Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors-Reference-Cited by-同舟云学术

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

Published:2019-09-19 Issue:2 Volume:371 Page:299-308
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Farrell Pamela J.,Zopf Christopher J.,Huang Huey-Jing^ORCID,Balakrishna Deepika,Holub Corine,Bilakovics James,Fanjul Andrea,Matuszkiewicz Jennifer,Plonowski Artur,Rolzin Paul,Banerjee Urmi,Ermolieff Jacques,Cheruvallath Zacharia S.,McBride Christopher,Bartkowski Darian,Mazur Crystal,Pachori Alok,Larson Christopher J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference29 articles.

2. Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice

3. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1;Cheruvallath;Bioorg Med Chem Lett,2016

4. Treatment of Cells with the Angiogenic Inhibitor Fumagillin Results in Increased Stability of Eukaryotic Initiation Factor 2-Associated Glycoprotein, p67, and Reduced Phosphorylation of Extracellular Signal-Regulated Kinases

5. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methionine aminopeptidases: Potential therapeutic target for microsporidia and other microbes;Journal of Eukaryotic Microbiology;2024-07-22

2. An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma;European Journal of Haematology;2024-07-12

3. Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity;Molecular Cancer Therapeutics;2024-03-25

4. Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity;2024-03-03

5. Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity;Trends in Pharmacological Sciences;2021-10